Results 231 to 240 of about 413,633 (296)

The association between chronic pain and non‐fatal overdose in people who inject drugs: Longitudinal cohort study in Montreal, Canada, 2017 to 2025

Addiction, EarlyView.
Abstract Background and aims The prevalence of chronic pain is elevated among people who inject drugs. Chronic pain may motivate drug use, potentially increasing the risk of non‐fatal overdose. We aimed to estimate the association between chronic pain and non‐fatal overdose in people who inject drugs.
Sarah Larney, Geng Zang, Harika Dasari, M. Gabrielle Pagé, Farzaneh Vakili, Adelina Artenie, Valérie Martel‐Laferrière, Nanor Minoyan, Sasha Udhesister, Julie Bruneau   +9 more
wiley   +1 more source

Real-World Utilization of Corticosteroids in Severe Alcoholic Hepatitis: Eligibility, Response, and Outcomes. [PDF]

Medicina (Kaunas)
Singeap AM, Minea H, Petrea O, Robea MA, Balmuș IM, Duta R, Ilie OD, Cimpoesu CD, Stanciu C, Trifan A.   +9 more
europepmc   +1 more source

Clinical Need and Research Investment for Liver Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Liver cancer incidence and mortality rates have been rising in comparison to other common cancers, but research funding has not been commensurate. ABSTRACT Aim This study aims to better understand factors driving the rising burden and costs of primary liver cancer (PLC) in Australia, identify key epidemiological trends, and ascertain investment in PLC ...
Romario Nguyen, Fatema Safri, Ankur Sharma, Jessica Howell, Stuart K. Roberts, Simone I. Strasser, Amany Zekry, Alan Wigg, Leon A. Adams, Michael Wallace, Golo Ahlenstiel, Eleonora Feletto, Karen Canfell, Tracey O'Brien, Jacob George, Liang Qiao   +15 more
wiley   +1 more source

[Corrigendum] Ginsenoside Rg1 inhibits inflammatory responses via modulation of the nuclear factor‑κB pathway and inhibition of inflammasome activation in alcoholic hepatitis. [PDF]

Int J Mol Med
Li J, Yang C, Zhang S, Liu S, Zhao L, Luo H, Chen Y, Huang W.   +7 more
europepmc   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source

Disrupted balance between pro-inflammatory lipid mediators and anti-inflammatory specialized pro-resolving mediators is linked to hyperinflammation in patients with alcoholic hepatitis. [PDF]

Front Immunol
Li W, Xia Y, Yang J, Sanyal AJ, Shah VH, Chalasani NP, Yu Q.   +6 more
europepmc   +1 more source

Impact of Single Viable Hepatocellular Carcinoma ≤ 3 cm on Survival After Liver Transplantation

ANZ Journal of Surgery, EarlyView.
An Australian multi‐centre cohort study shows significantly lower 5‐year HCC‐specific mortality for those with no viable disease compared to those with a single viable tumour ≤ 3 cm, on imaging prior to transplantation. A lower AFP level and complete response on mRECIST criteria also reduced risk.
Lauren C. Y. Tang, Eunice Lee, Avik Majumdar, Ted Stoklosa, Danny Con, William Chung, Emily Nash, Adam Testro, Michael Fink, Simone Strasser, Ken Liu, David G. Bowen, Marie Sinclair   +12 more
wiley   +1 more source

The mitochondrial biliverdin exporter ABCB10 in hepatocytes mitigates neutrophilic inflammation in alcoholic hepatitis. [PDF]

Redox Biol
Gutierrez V, Kim-Vasquez D, Shum M, Yang Q, Dikeman D, Louie SG, Shirihai OS, Tsukamoto H, Liesa M.   +8 more
europepmc   +1 more source

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala, Sameer Rao, Manas Gunani, Kajol Shah, Anand V. Kulkarni, Karn Wijarnpreecha, Daniel Q. Huang, Pojsakorn Danpanichkul, Ahmed Al‐Khazraji, Kaveh Hajifathalian, Vivek Lingiah, Paul Gaglio, Nikki Duong, Christine Gerula   +13 more
wiley   +1 more source

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet, Elisabetta Degasperi, Annarosa Cussigh, Elisabetta Fontanini, Maria Paola Anolli, Floriana Facchetti, Riccardo Perbellini, Dana Sambarino, Sara Uceda Renteria, Mariapaola Callegaro, Davide Bitetto, Elisa Fumolo, Ezio Fornasiere, Elena Garlatti Costa, Edmondo Falleti, Pietro Lampertico, Pierluigi Toniutto   +16 more
wiley   +1 more source